Study was stopped prior to study start date due to business decision.

The main purpose of this study is to evaluate a novel approach for insulin glargine (LY2963016) titration for insulin-naïve adults with type 2 diabetes (T2D)

The study will last about 6 months.

Inclusion Criteria:

• Adults with type 2 diabetes as diagnosed by endocrinologist
• No insulin over past 3 months
• Inadequate glycemic control with A1c ≥8.0% at or within 1 month prior to screening visit
• No history of diabetic ketoacidosis (DKA) or severe hypoglycemia leading to mental status change in the past 6 months
• Willingness and ability to follow the protocol including willingness to commence basal insulin, wear CGM, and communicate with healthcare provider.

Exclusion Criteria:

• Contraindication to use of insulin glargine (e.g., allergy)
• Impaired recognition of hypoglycemia by the participant (as judged by the investigator)

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.